1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Timing of lesional increases in size (percentage of total group A or B lesions beginning to increase in size at a given timepoint)
Time since SRSGroup A (n = 81 lesions)aGroup B (n = 83 lesions)a
6 weeks30.9%0%
3 months16.0%20.5%
4.5 months7.4%29%
6 months12.3%33%
7.5 months4.9%8.5%
9 months6.2%2.5%
10.5 months3.7%1%
12 months6.2%2.5%
13.5 months2.5%1%
15 months1.2%0%
16.5 months2.5%1%
18 months3.7%0%
19.5 months0%0%
21 months2.5%1%
22.5 months0%0%
24 months0%0%
  • 

    ↵a  Group A denotes lesions that increased in size to >120% of the pretreatment volume (ie, each timepoint is compared with the initial treatment volume). Group B denotes lesions whose volumes fluctuated in size during follow-up but never increased to a volume exceeding 120% of the pretreatment volume (ie, each timepoint is compared with both the initial treatment and prior time point volumes).